Objective and samples:
- To detect antibodies againts NF155, nodal neurofascin and CNTN1 in CIDP patients for samples 19-196 and 19-197 (ICQ).
- To confirm negativity in a NF155 positive patient pre and post-treatment with a negative ELISA (174-18, 171-08, 15-192, 15-193). To confirm negativity in a CNTN1 positive patient with a negative ELISA (144-20).
- To confirm positivity for IgM towards NF155 in a positive patient from Doppler (positive ELISA).
ICC NF155/NF140/NF186:
- Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/100 in 5% goat serum in PBS.
- Primary antibody: AF3235 diluted 1/1000.
- Secondary antibodies: GAC488 + GAH 594 IgG (1/1000).
- Vectashield mounting medium.
CNTN1 ICC:
- Blocking solution: Rabbit serum diluted 1/40 in PBS.
- Patient’s sera diluted 1/100 for IgG with rabbit serum 1/40.
- Primary antibody: AF904 diluted 1/1000.
- Secondary antibodies: RAG 488 + RAH 594 IgG (1/1000)
- Vectashield mounting medium.
ICC NF155/NF140/NF186:
- Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/40 in 5% goat serum in PBS.
- Primary antibody: AF3235 diluted 1/1000.
- Secondary antibodies: GAC488 + GAH 594 IgM (1/1000).
- Vectashield mounting medium.
RESULTS:
- Samples 19-196 and 19-197 are negative for NF155/NF140/NF186 and CNTN1.
- Sample 144-20 is negative for CNTN1.
- Samples 174-18 and 171-08 are positive for NF155.
- Samples 15-192 and 15-193 are negative for NF155.
